Anti-CD39 antibodies
Inventors
Soros, Vanessa • Kovalenko, Maria • Corbin, John • BEERS, Courtney • Widboom, Paul Fredrick • Warfield, Joseph Robert
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11345757-B2
Publication Date
2022-05-31
Expiration Date
Abstract
Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
Core Innovation
The invention relates to isolated antibody molecules capable of binding to human CD39 (hCD39). The antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), with VHCDR1, VHCDR2, and VHCDR3 and VLCDR1, VLCDR2, and VLCDR3 defined by specified sequence sets, together with defined CDR pairings and sequence assignments.
The disclosure further provides antibody-related sequence embodiments using specified sequences and sequence identity or conservative substitution rules. It includes variable region and CDR framework and length constraints using Kabat and Chothia numbering, as well as defined CDR sets, pairings, and variant provisions for hCD39-binding antibody embodiments.
The disclosed antibody binding is characterized by binding and functional evaluation to human CD39, including affinity ranges and binding kinetics measured using surface plasmon resonance and Biolayer interferometry. The document maps CD39 extracellular domain epitopes to specific extracellular sequence regions and residues, and describes inhibition of CD39 enzymatic activity and extracellular ATPase-related processes linked to immune cell functions.
Claims Coverage
The claim coverage centers on isolated antibodies that bind human CD39 (hCD39), defined either by specific VH and VL CDR sequence sets or by fixed full heavy- and light-chain sequences. Across the independent claims, there are two inventive features.
Isolated anti-human CD39 antibody defined by VH/VL CDR sequence sets
An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VHCDR1, VHCDR2, and VHCDR3 are defined by sequence sets set forth in SEQ ID NOs, and the VLCDR1, VLCDR2, and VLCDR3 are defined by corresponding sequence sets set forth in SEQ ID NOs.
Isolated anti-human CD39 antibody defined by fixed SEQ ID heavy and light chains
An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain and a light chain, wherein the heavy chain comprises a molecule having a sequence consisting of SEQ ID NO: 255 and the light chain comprises a molecule having a sequence consisting of SEQ ID NO: 256.
The independent claims define anti-CD39 antibodies that bind human CD39 using either specified CDR sequence sets for VH and VL or specified full heavy- and light-chain sequences (SEQ ID NO: 255 and SEQ ID NO: 256). Dependent claims further cover nucleic acids, expression vectors, host cells, and production with recovery from cells or cell culture supernatant.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Therapeutic uses of anti-CD39 antibodies for cancer immunosuppression and other diseases.
Diagnostic methods using anti-CD39 antibodies.
Analytical uses using anti-CD39 antibodies.
Pharmaceutical compositions comprising the anti-CD39 antibodies.
Diagnostic compositions comprising the anti-CD39 antibodies.
Kits comprising the anti-CD39 antibodies.
Interested in licensing this patent?